MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.rmed.2024.107863

Медицинская библиотека · Respiratory medicine · 2024

Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis.

Yappalparvi Ambanna, Balaraman Ashok Kumar, Padmapriya G, Gaidhane Shilpa, Kaur Irwanjot, Lal Madan, Iqbal Suhaib, Prasad G V Siva, Pramanik Atreyi, Vishwakarma Teena, Malik Praveen, Sharma Promila, Punia Ankit, Jagga Megha, Lingamaiah Doddolla, Mehta Rachana, Sah Sanjit, Zahiruddin Quazi Syed, Abu Serhan Hashem, Shabil Muhammed, Bushi Ganesh

СтатьяМетаанализСистематический обзорПеревод в очереди

Аннотация

BACKGROUND

Chronic obstructive pulmonary disease (COPD) significantly impacts global health due to persistent airflow limitation and inflammation. Despite standard therapies, symptoms persist. Ensifentrine, targeting both bronchoconstriction and inflammation as a dual phosphodiesterase 3 and 4 inhibitor, offers a promising therapeutic advancement for COPD management. This meta-analysis evaluates the safety and efficacy of ensifentrine in improving lung function, dyspnea, and quality of life in COPD patients.

METHODS

We searched PubMed, Embase, and Web of Science through August 2024 for randomized controlled trials evaluating ensifentrine in COPD patients over a minimum of four weeks. Data extraction and screening utilized Knowledge software, and meta-analyses were performed using R v4.4 with a random-effects model.

RESULTS

From 206 studies identified, four met our inclusion criteria. Ensifentrine improved FEV1 significantly at a dose of 3 mg (LS mean difference: 40.90 mL; 95 % CI: 19.65-62.15). It also improved dyspnea as measured by the Transition Dyspnea Index (TDI) (LS mean difference: 0.91; 95 % CI: 0.61-1.21) and quality of life according to the St. George's Respiratory Questionnaire-C (SGRQ-C) scores (LS mean difference: -1.92; 95 % CI: -3.28 to -0.55). Safety profiles were comparable between the ensifentrine and placebo groups, with no significant increase in treatment-emergent adverse events (TEAEs) (RR: 1.02; 95 % CI: 0.94-1.10).

CONCLUSION

Ensifentrine significantly enhances lung function, reduces dyspnea, and improves quality of life in COPD patients, especially at a 3 mg dose. These benefits, coupled with a stable safety profile, support its use as an adjunctive therapy in COPD management.

Для цитирования: Yappalparvi Ambanna, Balaraman Ashok Kumar, Padmapriya G, Gaidhane Shilpa, Kaur Irwanjot, Lal Madan, Iqbal Suhaib, Prasad G V Siva, Pramanik Atreyi, Vishwakarma Teena, Malik Praveen, Sharma Promila, Punia Ankit, Jagga Megha, Lingamaiah Doddolla, Mehta Rachana, Sah Sanjit, Zahiruddin Quazi Syed, Abu Serhan Hashem, Shabil Muhammed, Bushi Ganesh. Safety and efficacy of ensifentrine in COPD: A systemic review and meta-analysis.. Respiratory medicine. 2024. DOI: 10.1016/j.rmed.2024.107863.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.